KIRSTEN RAT SARCOMA (KRAS) PG12C MUTATION

Clinical trials for KIRSTEN RAT SARCOMA (KRAS) PG12C MUTATION explained in plain language.

Never miss a new study

Get alerted when new KIRSTEN RAT SARCOMA (KRAS) PG12C MUTATION trials appear

Sign up with your email to follow new studies for KIRSTEN RAT SARCOMA (KRAS) PG12C MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug combo trial targets 'Undruggable' cancer mutation

Disease control Ongoing

This early-stage trial is testing the safety and effectiveness of a drug called sotorasib, both by itself and combined with other cancer therapies. It is for adults with advanced solid tumors that have a specific genetic change known as the KRAS p.G12C mutation. The main goal is …

Matched conditions: KIRSTEN RAT SARCOMA (KRAS) PG12C MUTATION

Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control

Last updated Mar 27, 2026 12:40 UTC

KIRSTEN RAT SARCOMA (KRAS) PG12C MUTATION

Get alerted when new KIRSTEN RAT SARCOMA (KRAS) PG12C MUTATION trials appear

New drug combo trial targets 'Undruggable' cancer mutation